vigabatrin therapy have all had either a useful reduction (> 30%) in seizure frequency, and/ or significant amelioration of seizure manifestations, but none is seizure free. The starting dose of vigabatrin was reduced after the first 10 patients because seven of these patients suffered neurotropic side effects, in two cases severe. There were no severe neurotropic side effects in patients started on the lower dose of 1000 mg/day. All of our patients who showed a therapeutic response did so at a dose of 2000 mg/day or less, and there were no patients in whom increasing the dose beyond this produced any further response. 
